Latest Headlines

Latest Headlines

Bristol-Myers forges $1.25B deal to beef up fibrosis pipeline in Promedior buyout

Bristol-Myers Squibb has landed the rights to buy out Lexington, MA-based Promedior, paying $150 million upfront and committing a total of $1.25 billion to the deal--if the biotech's fibrosis drug comes through in Phase II studies.

New chief takes helm at Promedior and steers a course for Boston

Just a couple of months after Promedior lined up its $21.5 million D round for fibrosis drug work, a new CEO has stepped up to the helm with plans to abandon Philadelphia and head for the bustling biotech hub in Boston.

Promedior lands $21.5M D round for fibrosis pipeline

Right on schedule, Malvern, PA-based Promedior has landed a $21.5 million D round to advance its lead drug for a rare fibrotic ailment.

Promedior gains Dutch VC backing in $12M round

Malvern, PA-based Promedior has lined up a fresh $12 million injection of venture cash to get its lead drug into mid-stage trials for inflammatory and fibrotic diseases. And the developer burnished